Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

748.01 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
This Unstoppable Stock Has Gained 100,203% Over The Last 50 Years, Creating Many Millionaires in the Process. Here Are 3 Reasons I Think It Will Continue to Create Generational Wealth.
Eli Lilly has been a big-time winner for investors over the last several decades, and there are many reasons to believe the company is at the forefront of many new growth stories. 
Via The Motley Fool
Beyond Mounjaro and Zepbound: 6 Other Drugs That Could Be Blockbusters for Eli Lilly
This drugmaker should have a basketful of growth drivers over the next decade. 
Via The Motley Fool
Is Merck Stock Undervalued After Its Colossal Earnings Growth?
Merck has seen its earnings invert over the past 12 months, driving earnings grow in its sector. What's going on with this pharma giant? 
Via MarketBeat
Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead?
The huge demand for effective new weight management drugs has billionaire investors feeling bullish about this stock. 
Via The Motley Fool
AskSlim Market Week - Friday, Sept 6
An analysis and commentary on the financial markets. 
Via Talk Markets
Comparative Study: Eli Lilly And Industry Competitors In Pharmaceuticals Industry
Via Benzinga
Trade Pulse Power Inflow Alert: Eli Lilly Stock Rises Over 7 Points
Via Benzinga
Gilding The Lilly
Via Talk Markets
Innovent Bio hopes for plus-sized profits from obesity drug
Key Takeaways: Sales approval for the company’s anti-obesity drug mazdutide may drag out beyond this year, potentially allowing rival products to gain a market advantage The executive in charge of... 
Via Benzinga
Topics Retirement
Exposures Pension
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked. 
Via Benzinga
Exposures Product Safety
Stock Of The Day: Here's Why Weight-Loss Drug Maker Eli Lilly Has Reversed
Shares of Eli Lilly hit resistance at the $955 level. Now they are heading lower. These moves are due to investor psychology. 
Via Benzinga
This Big Move by Eli Lilly May Solve the Weight Loss Drug Market's Biggest Problem
The weight loss drug market may soon be worth $100 billion. 
Via The Motley Fool
Shorting The Fatties
Eli Lilly (LLY) has traditionally scared me. It is sporting a P/E in the triple digits, which is normally what you would associate with a new biotech company at the cusp of curing cancer, not an... 
Via Talk Markets
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation. Other drugs also affected. 
Via Benzinga
Battle Over Compounded Weight-Loss Medications - Sustainability and Regulation
Explore how Hims & Hers competes with big pharma amid weight-loss drug shortages, offering cheaper alternatives and facing sustainability challenges. 
Via Benzinga
Eli Lilly's Once-Weekly Insulin Shows Non-Inferior Blood Sugar Reduction Vs Frequently Used Daily Insulins In Long Term Trials
Eli Lilly's Weekly Insulin Efsitora Meets Phase 3 Goals, Offering Improved Blood Sugar Control in Type 2 Diabetes. 
Via Benzinga
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.
Lilly just lowered the price of Zepbound. 
Via The Motley Fool
Why Walgreens Boots Alliance Fell Another 22% in August
The retail pharmacy giant faces ever-mounting headwinds. 
Via The Motley Fool
How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, Apple
The companies are well-known for their obesity treatments and could reach a $1 trillion market cap before carmaker Tesla. 
Via Investor's Business Daily
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
BioAge Labs a biotech company focused on therapies for metabolic diseases, has filed for a $100 million IPO. Founded in 2015, the company plans to list on Nasdaq under the symbol BIOA. Their lead drug,... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Top Medical Stocks To Hedge Against The September Effect
While the Fed will likely cut interest rates in the coming weeks, September has historically been the most challenging month for stocks. Here are three top medical stocks to hedge against the September... 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Eli Lilly Trades Near All-Time High: Check Out The IBD 50, Big Cap 20, Other Top Stock Lists
Lilly, which traces it roots in the industry back 150 years to its founding by chemist Eli Lilly, boasts a best-possible 99 Composite Rating. 
Via Investor's Business Daily
3 Big Winners From The Q2 Earnings Season: LLY, LMT, META
The 2024 Q2 earnings season is slowly grinding to a halt, with the majority of S&P 500 companies already delivering quarterly results. All three listed here posted robust results with shares of each... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than... 
Via Benzinga
Topics Economy
Exposures Interest Rates
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Will September Bring A Rebound In Google Stock Amid New Antitrust Trial?
Google stock could face a headline risk from a new antitrust trial starting in September involving advertising technology. 
Via Investor's Business Daily
Eli Lilly Launches Discounted Mounjaro And Zepbound As Fight Against Compounded Imitations Escalates Amid Ongoing FDA Shortage Status Debate
Eli Lilly is intensifying its efforts to combat imitation versions of its popular appetite-suppressing drugs, Mounjaro and Zepbound. 
Via Benzinga
Exposures Product Safety
2 No-Brainer Growth Stocks to Buy With $1,000 Right Now
These disruptive stocks could reap generous rewards for long-term investors. 
Via The Motley Fool
Market Thoughts This Labor Day Weekend
For this long weekend, I am offering you food for thought. In the overall macro theme, I am sticking to this for time being: Stagflation - The Fed can’t fix it with a huge reduction in rates, that will... 
Via Talk Markets
Topics Economy
Exposures Interest Rates
S&P 500 Giants Meta, Eli Lilly Lead 5 Stocks Near Buy Points
While the Nasdaq lagged last week, the S&P 500 entered a power trend Friday. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.